olfactory receptor family 5 subfamily A member 1Genealiases: OR11-249 · OR5A1P · OST181
Q-omics provides the consensus-scored OR5A1 profile across patient tissues and cancer cell-line models. OR5A1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, OR5A1 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, OR5A1 RNA expression shows 6,707 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, THCA, and STAD as cancer lineages where OR5A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5A1 survival associations across molecular data types. OR5A1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5A1 RNA expression–survival associations across cancer types. High OR5A1 expression shows unfavorable associations in SKCM, KIRC, KICH, READ, BRCA and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for OR5A1 RNA expression.
This table summarizes OR5A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR5A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5A1 shows higher tumor expression in THCA. The THCA box plot shows higher OR5A1 RNA expression in tumor versus normal tissue (log2 FC = +0.193, t-test p < 0.001).
This table shows molecular features associated with OR5A1 in patient tissues and cancer cell lines. In patient samples, OR5A1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR5A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
